States that could decide the outcome feel about both candidates. Post Debate Polling from the New York times and Sienna College has this race between Kamala Harris and Donald Trump deadlocked nationally. But its a different story when you zoom in to battleground pennsylvania. Vice president harris is up 4 points among likely voters there, albeit within the margin of error. Well dig deeper into the numbers, including why the share of voters who wanted to learn more about harris before last Weeks Debate have largely remained unconvinced. New Quinnipiac Polling also has the Vice President leading trump in pennsylvania as well as in michigan and wisconsin. Though all three of those key State Results are also within the margin of error. In other words, a dead heat. So what are both candidates doing today to connect with voters . Harris is continuing her battleground sweep, shell be in Michigan Today alongside Oprah Winfrey for a live Stream Event aimed at urging americans to register to vot
investigation. and nothing will ever stop us from keeping america secure. norah: political showdown. the manhattan district attorney sue is a member of congress to keep republicans from interfering in the donald trump case. a cbs news investigation, how china built its own boeing 737. do you feel like they stole an airliner? i don t feel that way, i think that is a fact. norah: our tax series, how you can maximize your refund in a year where many of americans will get less cash back. so used to getting something back all of the time, and all of a sudden have to write a check, it s a rude awakening. norah: and meet an air force family flying into the history books. carrying hopefully the next generation bomber pilot, while flying sernic, was quite the memory. norah: good evening, and thank you for joining us on this busy tuesday night. we do want to begin with some breaking news from louisville, kentucky, where police just released chilling and
X4 Pharmaceuticals (XFOR), focused on rare diseases of the immune system, announced Monday that the U.S. Food and Drug Administration or FDA has approved XOLREMDI (mavorixafor) capsules for use in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis).